In this study we randomly compared the estradiol eluting stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent.
17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease / Airoldi, F., Di Mario, C., Ribichini, F., Presbitero, P., Sganzerla, P., Ferrero, V., Vassanelli, C., Briguori, C., Carlino, M., Montorfano, M., Biondi-Zoccai Giuseppe, G.L., Chieffo, A., Ferrari, A., Colombo, A.. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - (2005). [10.1016/j.amjcard.2005.04.040]
17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease
Montorfano M;Chieffo Alaide;
2005-01-01
Abstract
In this study we randomly compared the estradiol eluting stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
